Research & Development

Roche receives FDA acceptance for giredestrant combo NDA

Roche has obtained acceptance from the US Food and Drug Administration (FDA) for its new drug application (NDA) submitted for giredestrant, an oral therapy, along with everolimus to treat breast cancer.

Boehringer Ingelheim and NIPER sign MoU on pharmaceutical research

Boehringer Ingelheim India has signed a memorandum of understanding (MoU) to enhance pharmaceutical education and research collaboration.

Syngene and VivaMed collaborate on therapeutic programmes

Syngene International has entered a strategic collaboration with VivaMed BioPharma to advance AI-derived repurposed therapeutic programmes.

Novartis enters licensing agreement with UNP for peptide therapeutics

Novartis has signed a research partnership and licensing agreement with Unnatural Products (UNP) valued at up to $1.7bn to develop macrocyclic peptide therapeutics targeting cardiovascular diseases.

MSD and Mayo Clinic team up to advance AI in drug development

Merck & Co (MSD) and Mayo Clinic have entered a research and development collaboration to utilise AI, advanced analytics, and multimodal clinical data in support of drug discovery and precision medicine.

Evogene and QUT partner on AI-based cancer therapies

Evogene has partnered with Queensland University of Technology (QUT) in Australia to progress the development of AI-driven small molecule cancer therapeutics.

J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC

Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for a new monthly dosing schedule for the combination therapy Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) to treat patients with advanced, epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Teijin and Aska Pharmaceutical agree for gynaecological drug development

Teijin Pharma has signed a joint research agreement with Tokyo-based Aska Pharmaceutical to develop small-molecule drug candidates for gynaecological diseases.

ExCellThera secures German NUB Status 1 listing for Zemcelpro

ExCellThera and its wholly owned subsidiary Cordex Biologics have received a Status 1 listing from the Neue Untersuchungs- und Behandlungsmethoden (NUB) programme in Germany for Zemcelpro (dorocubicel), also known as UM171 Cell Therapy.